See more : DaVita Inc. (0I7E.L) Income Statement Analysis – Financial Results
Complete financial analysis of Mabion S.A. (MAB.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mabion S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Delica Foods Holdings Co., Ltd. (3392.T) Income Statement Analysis – Financial Results
- biote Corp. (BTMD) Income Statement Analysis – Financial Results
- American Copper Development Corporation (ACDX.CN) Income Statement Analysis – Financial Results
- PT Inti Agri Resources Tbk (IIKP.JK) Income Statement Analysis – Financial Results
- China Ecotourism Group Limited (1371.HK) Income Statement Analysis – Financial Results
Mabion S.A. (MAB.WA)
About Mabion S.A.
Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 151.68M | 163.98M | 56.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.73M | 829.70K | 5.80K | 884.78K | 985.38K | 1.53M | 0.00 |
| Cost of Revenue | 37.10M | 98.00M | 20.99M | 9.83M | 466.00K | 797.00K | 971.00K | 758.00K | 5.64M | 4.22M | 6.00K | 1.84M | -7.00M | -1.18M | 5.98K |
| Gross Profit | 114.58M | 65.99M | 35.89M | -9.83M | -466.00K | -797.00K | -971.00K | -758.00K | -2.91M | -3.39M | -200.00 | -956.22K | 7.99M | 2.70M | -5.98K |
| Gross Profit Ratio | 75.54% | 40.24% | 63.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.29% | -408.74% | -3.45% | -108.07% | 810.76% | 177.05% | 0.00% |
| Research & Development | 6.25M | 15.12M | 13.60M | 35.73M | 40.71M | 44.93M | 43.26M | 44.22M | 37.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 40.18M | 28.66M | 10.99M | 7.95M | 3.63M | 3.22M | 7.07M | 3.18M | 5.18M | 1.09M | 4.05M | 1.13M | 7.88M | 93.06K | 23.14K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -988.00K | 309.00K | 186.00K | 166.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 40.18M | 28.66M | 10.99M | 7.95M | 3.63M | 3.22M | 7.07M | 3.18M | 4.19M | 1.40M | 4.24M | 1.30M | 7.88M | 93.06K | 23.14K |
| Other Expenses | 13.10M | -4.29M | 18.98M | 10.97M | 18.25M | 16.03M | 12.05M | 8.28M | -6.81M | -5.42M | -4.01M | -3.25M | 1.97M | 2.23M | 360.65K |
| Operating Expenses | 59.52M | 39.49M | 43.58M | 54.65M | 62.59M | 63.38M | 61.41M | 54.92M | -6.81M | -5.42M | -4.01M | -3.25M | 9.86M | 2.33M | 383.80K |
| Cost & Expenses | 96.62M | 137.49M | 64.56M | 54.65M | 63.05M | 64.18M | 62.38M | 55.68M | -6.81M | -5.42M | -4.01M | -3.25M | 2.85M | 1.15M | 389.78K |
| Interest Income | 718.00K | 287.00K | 405.00K | 34.00K | 582.00K | 915.00K | 31.00K | 25.00K | 29.00K | 0.00 | 0.00 | 0.00 | 677.07K | 126.47K | 0.00 |
| Interest Expense | 1.04M | 1.70M | 1.29M | 1.41M | 751.00K | 1.92M | 1.72M | 217.00K | 235.00K | 0.00 | 0.00 | 0.00 | 77.25K | -2.72K | 0.00 |
| Depreciation & Amortization | 7.20M | 8.98M | 8.85M | 9.83M | 11.11M | 10.66M | 8.05M | 6.94M | 6.81M | 5.42M | 4.01M | 3.25M | 718.03K | 83.40K | 8.03K |
| EBITDA | 58.31M | 32.95M | 118.00K | -44.27M | -51.79M | -55.76M | -47.90M | -48.66M | -37.65M | 830.00K | 5.80K | 884.80K | -544.53K | 460.35K | -357.40K |
| EBITDA Ratio | 38.45% | 18.90% | 4.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | -116.68% | 30.14% | 0.00% |
| Operating Income | 55.06M | 22.02M | -6.07M | -54.65M | -63.27M | -64.63M | -62.38M | -55.53M | -4.08M | -4.59M | -4.01M | -2.36M | -1.87M | 376.95K | -389.78K |
| Operating Income Ratio | 36.30% | 13.43% | -10.66% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -149.29% | -553.07% | -69,089.66% | -267.14% | -189.54% | 24.68% | 0.00% |
| Total Other Income/Expenses | -5.17M | -6.18M | -423.00K | -1.12M | -466.00K | -2.39M | 4.49M | -295.00K | -443.00K | 115.00K | 129.10K | 189.90K | 599.82K | 129.19K | -8.06K |
| Income Before Tax | 49.89M | 22.04M | -10.26M | -55.77M | -63.74M | -68.87M | -57.89M | -55.83M | -4.52M | -4.53M | -3.88M | -2.17M | -1.27M | 506.14K | -397.84K |
| Income Before Tax Ratio | 32.89% | 13.44% | -18.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -165.50% | -546.43% | -66,863.79% | -245.68% | -128.67% | 33.13% | 0.00% |
| Income Tax Expense | 8.63M | -1.15M | -12.16M | 1.42M | 970.00K | -2.77M | 6.21M | 70.00K | -6.74M | -5.49M | -4.00M | -3.30M | 86.14K | 34.69K | -69.09K |
| Net Income | 41.27M | 23.19M | 1.90M | -57.19M | -64.71M | -68.87M | -57.89M | -55.83M | -4.60M | -4.46M | -3.89M | -2.12M | -1.35M | 471.45K | -328.75K |
| Net Income Ratio | 27.21% | 14.14% | 3.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -168.20% | -537.69% | -67,089.66% | -239.77% | -137.41% | 30.86% | 0.00% |
| EPS | 2.55 | 1.44 | 0.12 | -4.17 | -4.72 | -5.26 | -4.91 | -4.84 | -0.42 | -0.44 | -0.49 | -0.40 | -0.28 | 0.07 | -0.05 |
| EPS Diluted | 2.55 | 1.44 | 0.12 | -4.17 | -4.72 | -5.26 | -4.91 | -4.84 | -0.42 | -0.44 | -0.49 | -0.40 | -0.28 | 0.07 | -0.05 |
| Weighted Avg Shares Out | 16.16M | 16.16M | 15.56M | 13.72M | 13.72M | 13.09M | 11.80M | 11.54M | 10.88M | 10.06M | 7.93M | 5.33M | 4.88M | 6.90M | 6.90M |
| Weighted Avg Shares Out (Dil) | 16.16M | 16.16M | 15.56M | 13.72M | 13.72M | 13.09M | 11.80M | 11.55M | 10.88M | 10.06M | 7.93M | 5.33M | 4.88M | 6.90M | 6.90M |
No news found for: MAB.WA
Source: https://incomestatements.info
Category: Stock Reports